

CITATION REPORT

List of articles citing

Clinical presentation and management of mTOR inhibitor-associated stomatitis

DOI: 10.1016/j.oraloncology.2011.08.009
Oral Oncology, 2011, 47, 998-1003.

Source: <https://exaly.com/paper-pdf/51088076/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
90	Everolimus/ridaforolimus. <i>Reactions Weekly</i> , 2011 , &NA;, 20-21	0	
89	Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. <i>Ca-A Cancer Journal for Clinicians</i> , 2012 , 62, 400-22	220.7	252
88	Practical management of everolimus-related toxicities in patients with advanced solid tumors. <i>Onkologie</i> , 2013 , 36, 295-302		25
87	Everolimus: side effect profile and management of toxicities in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 140, 453-62	4.4	61
86	[Medical treatment of renal cell carcinoma]. <i>Progres En Urologie</i> , 2013 , 23, 1225-37	0.9	2
85	Biological therapies in breast cancer: common toxicities and management strategies. <i>Breast</i> , 2013 , 22, 1009-18	3.6	20
84	Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2013 , 116, e110-6	2	20
83	The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer. <i>Current Oncology Reports</i> , 2013 , 15, 14-23	6.3	19
82	A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. <i>Oral Oncology</i> , 2013 , 49, 293-8	4.4	91
81	Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. <i>Clinical Cancer Research</i> , 2013 , 19, 5474-84	12.9	58
80	The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events. <i>Therapeutic Advances in Medical Oncology</i> , 2013 , 5, 286-300	5.4	5
79	Mammalian target of rapamycin inhibitor-associated stomatitis. <i>Future Oncology</i> , 2013 , 9, 1883-92	3.6	61
78	IRAK4 turns IL-10+ phospho-FOXO+ monocytes into pro-inflammatory cells by suppression of protein kinase B. <i>European Journal of Immunology</i> , 2013 , 43, 1630-42	6.1	13
77	Adverse event management of oral mucositis in patients with breast cancer. <i>Breast Care</i> , 2014 , 9, 232-7	2.4	6
76	Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. <i>Annals of Oncology</i> , 2014 , 25, 763-773	10.3	58
75	Oral ulcerations as a sequela of tacrolimus and mycophenolate mofetil therapy. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2014 , 118, e175-8	2	14
74	Levels of sirolimus in saliva and blood following mouthwash application. <i>Oral Diseases</i> , 2014 , 20, 768-72	3.5	7

73	Oral mucosal injury caused by cancer therapies: current management and new frontiers in research. <i>Journal of Oral Pathology and Medicine</i> , 2014 , 43, 81-90	3.3	39
72	Oral Mucosal Injury in Oncology Patients. <i>Current Oral Health Reports</i> , 2014 , 1, 190-195	1.2	
71	Strategies for the management of adverse events associated with mTOR inhibitors. <i>Transplantation Reviews</i> , 2014 , 28, 126-33	3.3	180
70	Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer. <i>Thyroid</i> , 2014 , 24, 1329-40	6.2	28
69	Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: considerations for oncologists. <i>Clinical Breast Cancer</i> , 2014 , 14, 297-308	3	20
68	[Oral toxicity of targeted anticancer therapies]. <i>Annales De Dermatologie Et De Venereologie</i> , 2014 , 141, 354-63	0.3	10
67	Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2015 , 19, 468-74	1.1	12
66	Current management of mTOR inhibitor-associated stomatitis. <i>Breast Cancer Management</i> , 2015 , 4, 255-264		
65	Recognition and Management of Oral Mucosal Injury Caused by Mammalian Target of Rapamycin Inhibitors: A Case Series. <i>Case Reports in Oncology</i> , 2015 , 8, 369-77	1	6
64	mTOR kinase: a possible pharmacological target in the management of chronic pain. <i>BioMed Research International</i> , 2015 , 2015, 394257	3	45
63	Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2015 , 21, 433-42	1.7	7
62	Mammalian target of rapamycin inhibitor-associated stomatitis in hematopoietic stem cell transplantation patients receiving sirolimus prophylaxis for graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 503-8	4.7	13
61	Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 847-58	3.5	11
60	Levels of sirolimus in saliva and blood following oral topical sustained-release varnish delivery system application. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 969-74	3.5	8
59	Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2. <i>Neoplasia</i> , 2015 , 17, 279-88	6.4	43
58	Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. <i>Cancer Investigation</i> , 2015 , 33, 70-7	2.1	23
57	Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. <i>Annals of Oncology</i> , 2015 , 26 Suppl 5, v139-51	10.3	115
56	Adverse drug events in the oral cavity. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015 , 119, 35-47	2	82

55	mTOR inhibitor-associated stomatitis (MIAS) in three patients with cancer treated with everolimus. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015 , 119, e13-9	2	10
54	Everolimus-associated stomatitis in a patient who had renal transplant. <i>BMJ Case Reports</i> , 2016 , 2016,	0.9	4
53	Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. <i>ELife</i> , 2016 , 5,	8.9	184
52	Safety of mTOR inhibitors in breast cancer. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1075-85	4.1	6
51	The dog aging project: translational geroscience in companion animals. <i>Mammalian Genome</i> , 2016 , 27, 279-88	3.2	75
50	Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. <i>Cancer Medicine</i> , 2016 , 5, 1897-907	4.8	51
49	Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2017 , 25, 1713-1739	3.9	82
48	Everolimus-related adverse events in neuroendocrine tumors and comparative considerations with breast and renal cancer: a critical overview. <i>Expert Opinion on Orphan Drugs</i> , 2017 , 5, 525-536	1.1	
47	Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2017 , 18, 654-662	21.7	117
46	Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator-initiated prospective study. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 1182-1189	2.6	
45	Berunda Polypeptides: Multi-Headed Fusion Proteins Promote Subcutaneous Administration of Rapamycin to Breast Cancer. <i>Theranostics</i> , 2017 , 7, 3856-3872	12.1	12
44	Breast cancer patients have increased risk of developing mTOR inhibitor-associated stomatitis. <i>Oral Diseases</i> , 2018 , 24, 207-209	3.5	1
43	Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer. <i>Journal of the American Dental Association</i> , 2018 , 149, 291-298	1.9	11
42	Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation. <i>Journal of Pineal Research</i> , 2018 , 64, e12461	10.4	85
41	Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients. <i>Oral Diseases</i> , 2018 , 24, 144-171	3.5	12
40	Prevention of Stomatitis: Using Dexamethasone-Based Mouthwash to Inhibit Everolimus-Related Stomatitis. <i>Clinical Journal of Oncology Nursing</i> , 2018 , 22, 211-217	1.1	
39	Everolimus-associated perianal ulcers in an eight-month-old heart transplant recipient. <i>Pediatric Transplantation</i> , 2018 , 22, e13072	1.8	0
38	Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1184	5.6	12

37	Oral Mucosal Injury Caused by Targeted Cancer Therapies. <i>Journal of the National Cancer Institute Monographs</i> , 2019 , 2019,	4.8	5
36	A review and guide to drug-associated oral adverse effects-Oral mucosal and lichenoid reactions. Part 2. <i>Journal of Oral Pathology and Medicine</i> , 2019 , 48, 637-646	3.3	3
35	Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 767-774	5.5	30
34	Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study. <i>Oncologist</i> , 2019 , 24, 1153-1158	5.7	5
33	Translating concepts of systems medicine to the clinic. 2020 , 409-427		0
32	Oral manifestations of allograft recipients immediately before and after kidney transplantation. <i>Acta Odontologica Scandinavica</i> , 2020 , 78, 217-222	2.2	1
31	Adverse Drug Events in the Oral Cavity. <i>Dermatologic Clinics</i> , 2020 , 38, 523-533	4.2	3
30	Oral chronic graft-versus-host disease: What the general dental practitioner needs to know. <i>Journal of the American Dental Association</i> , 2020 , 151, 846-856	1.9	4
29	Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review. <i>Cancers</i> , 2020 , 12,	6.6	22
28	Novel update of interventional strategies of vascular aging in humans. <i>Aging Medicine (Milton (N S W))</i> , 2020 , 3, 146-150	3.5	0
27	Berunda Polypeptides Carrying Rapalogues Inhibit Tumor mTORC1 Better than Oral Everolimus. <i>Biomacromolecules</i> , 2020 , 21, 3038-3046	6.9	0
26	The quest to slow ageing through drug discovery. <i>Nature Reviews Drug Discovery</i> , 2020 , 19, 513-532	64.1	91
25	IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. <i>Cancers</i> , 2020 , 12,	6.6	10
24	Nanotoxicology of an Elastin-like Polypeptide Rapamycin Formulation for Breast Cancer. <i>Biomacromolecules</i> , 2020 , 21, 1091-1102	6.9	9
23	Rapamycin induced hyperglycemia is associated with exacerbated age-related osteoarthritis.		0
22	The Clinical Pharmacology and Toxicity Profile of Rapalogs. 2016 , 161-189		4
21	Management of mTOR inhibitors oral mucositis: current state of knowledge. <i>Journal of Oral Medicine and Oral Surgery</i> , 2019 , 25, 11	0.7	1
20	Intralesional corticosteroid injection as an effective treatment method for oral lesions: a meta-analysis. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 56,	1.8	1

19	Preventive effect of gargling with sodium azulene sulfonate on everolimus-induced stomatitis. <i>Palliative Care Research</i> , 2014 , 9, 122-127	0.1	2
18	Reduced expression of C/EBP β LIP extends health and lifespan in mice. <i>ELife</i> , 2018 , 7,	8.9	11
17	Rapamycin-induced hyperglycemia is associated with exacerbated age-related osteoarthritis. <i>Arthritis Research and Therapy</i> , 2021 , 23, 253	5.7	3
16	Oral Complications in Hematopoietic Stem Cell Transplantation Survivorship. 172-182		
15	Reduced expression of C/EBP β LIP extends health- and lifespan in mice.		
14	Usefulness of Dexamethasone Ointment for Preventing Everolimus-induced Stomatitis. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2018 , 44, 631-638	0.1	
13	The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. <i>Ca-A Cancer Journal for Clinicians</i> , 2021 ,	220.7	5
12	An unusual case of everolimus-associated recurrent oral ulcerations in heart transplant recipient. <i>Annali Di Stomatologia</i> , 2013 , 4, 22-3		
11	Drug-Specific Orofacial Complications of Novel Anti-cancer Therapies. 2022 , 153-169		
10	Oral Mucositis. 2022 , 49-97		1
9	Rapamycin Promotes the Expansion of Myeloid Cells by Increasing G-CSF Expression in Mesenchymal Stem Cells.. <i>Frontiers in Cell and Developmental Biology</i> , 2022 , 10, 779159	5.7	
8	Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer.. <i>Journal of Bone Oncology</i> , 2022 , 33, 100419	4.5	1
7	Data_Sheet_1.PDF. 2018 ,		
6	Oridonin Delays Aging Through the AKT Signaling Pathway. <i>Frontiers in Pharmacology</i> , 13,	5.6	1
5	Age-related diseases, therapies and gut microbiome: a new frontier for healthy aging. <i>Mechanisms of Ageing and Development</i> , 2022 , 111711	5.6	0
4	MyMD-1 improves health span and prolongs lifespan in old mice: A non-inferiority study to rapamycin.		0
3	Canonical and novel strategies to delay or reverse aging. 2023 , 225-239		0
2	Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). 2023 ,		0

1 Life on Magnet: Long-Term Exposure of Moderate Static Magnetic Fields on the Lifespan and Healthspan of Mice. **2023**, 12, 108

1